176 related articles for article (PubMed ID: 37223854)
1. The Oncogenic Role of Cyclin-Dependent Kinase Inhibitor 2C in Lower-Grade Glioma.
Zhu Q; Zhu Z; Renaud SJ; Hu L; Guo Y
J Mol Neurosci; 2023 Jun; 73(6):327-344. PubMed ID: 37223854
[TBL] [Abstract][Full Text] [Related]
2. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a prognostic gene expression signature for lower-grade glioma following surgery and adjuvant radiotherapy.
Qian DC; Marascio JA; Tobillo R; Lorenz JW; McCall NS; Neill SG; Hoang KB; Olson JJ; Eaton BR; Shu HG; Zhong J
Radiother Oncol; 2022 Oct; 175():93-100. PubMed ID: 35998839
[TBL] [Abstract][Full Text] [Related]
4. An independently validated survival nomogram for lower-grade glioma.
Gittleman H; Sloan AE; Barnholtz-Sloan JS
Neuro Oncol; 2020 May; 22(5):665-674. PubMed ID: 31621885
[TBL] [Abstract][Full Text] [Related]
5. PPP1R81 correlates with the survival and cell proliferation in lower-grade glioma.
Xiao F; Jie X; Zhou X; Guo Y; Sun GF; Lin L; Hu GW; Huang K; Guo H
Biosci Rep; 2023 May; 43(5):. PubMed ID: 37083601
[TBL] [Abstract][Full Text] [Related]
6. An autophagic gene-based signature to predict the survival of patients with low-grade gliomas.
Chen J; Li Y; Han X; Pan Y; Qian X
Cancer Med; 2021 Mar; 10(5):1848-1859. PubMed ID: 33591634
[TBL] [Abstract][Full Text] [Related]
7. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
8. CCNB2 is a novel prognostic factor and a potential therapeutic target in low-grade glioma.
Wang D; Sun H; Li X; Wang G; Yan G; Ren H; Hou B
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34908101
[TBL] [Abstract][Full Text] [Related]
9. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
10. A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis.
Xu J; Liu F; Li Y; Shen L
Cell Mol Neurobiol; 2022 Apr; 42(3):709-722. PubMed ID: 32894375
[TBL] [Abstract][Full Text] [Related]
11. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
12. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
14. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
15. ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy.
Cheng X; Liu Z; Liang W; Zhu Q; Wang C; Wang H; Zhang J; Li P; Gao Y
Int J Biochem Cell Biol; 2023 May; 158():106409. PubMed ID: 36997057
[TBL] [Abstract][Full Text] [Related]
16. Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma.
Lv L; Zhang Y; Zhao Y; Wei Q; Zhao Y; Yi Q
Front Cell Neurosci; 2021; 15():704344. PubMed ID: 34335194
[No Abstract] [Full Text] [Related]
17. Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma.
Wu F; Li GZ; Liu HJ; Zhao Z; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Li RP; Zhang W
J Pathol; 2020 Jul; 251(3):272-283. PubMed ID: 32418210
[TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
[TBL] [Abstract][Full Text] [Related]
19. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
[TBL] [Abstract][Full Text] [Related]
20. Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors.
Husemann K; Wolter M; Büschges R; Boström J; Sabel M; Reifenberger G
J Neuropathol Exp Neurol; 1999 Oct; 58(10):1041-50. PubMed ID: 10515227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]